our Premium Content: News alerts, weekly reports and conference planners

GENE:

NCOA1 (Nuclear Receptor Coactivator 1)

News alerts, weekly reports and conference planners

18d

Leptin Drives Breast Cancer Aggressiveness Acting Through the Activation of the NCOA1/STAT3 Pathway. (PubMed, Med Sci (Basel))

Obesity-associated hyperleptinemia enhances aggressiveness in BC through a mechanism involving LEPR-mediated activation pathways encompassing NCOA1/STAT3, which drive proliferation, migration, and EMT. This assigns a potential therapeutic utility for obesity-related advancements found within BC pathology.

18 days ago

Journal • BRCA Biomarker

CCND1 (Cyclin D1) • CDH1 (Cadherin 1) • LEP (Leptin) • NCOA1 (Nuclear Receptor Coactivator 1)

25d

Cross-Regional Transcriptome Data Reveal Transcriptional Abnormalities Associated with Lung Adenocarcinoma. (PubMed, Rep Biochem Mol Biol)

Our findings suggest that the expression levels of serglycin, ILK, ESD, and PLPD1 may play a significant role in the development of LAC. This information can be valuable for identifying potential treatment targets for lung cancer.

25 days ago

Journal

CD123 (Interleukin 3 Receptor Subunit Alpha) • SPARC (Secreted Protein Acidic And Cysteine Rich) • VIM (Vimentin) • IL3RA (Interleukin 3 Receptor Subunit Alpha) • KRT19 (Keratin 19) • AQP1 (Aquaporin 1) • BST1 (Bone Marrow Stromal Cell Antigen 1) • COL3A1 (Collagen Type III Alpha 1 Chain) • SMAD7 (SMAD Family Member 7) • TAGLN (Transgelin) • ADH1B (Alcohol Dehydrogenase 1B (Class I), Beta Polypeptide) • AIMP2 (Aminoacyl TRNA Synthetase Complex Interacting Multifunctional Protein 2) • AKAP12 (A-Kinase Anchoring Protein 12) • RGS2 (Regulator Of G Protein Signaling 2) • NCOA1 (Nuclear Receptor Coactivator 1)

2ms

GREB1-rearranged uterine tumour shares a common DNA methylation signature with ESR1-rearranged UTROSCT. (PubMed, Histopathology)

Overall, our findings confirm that GREB1-rearranged uterine tumours are part of the UTROSCT spectrum, though they frequently exhibit a more diffuse growth pattern and a higher degree of genomic instability.

2 months ago

Journal

ER (Estrogen receptor) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • NR4A3 (Nuclear receptor subfamily 4 group A member 3) • SS18 (SS18 Subunit Of BAF Chromatin Remodeling Complex) • NCOA2 (Nuclear Receptor Coactivator 2) • NCOA1 (Nuclear Receptor Coactivator 1)

2ms

Decoding UTROSCT heterogeneity: systematic clinicopathological evaluation combined with molecular profiling. (PubMed, J Pathol Clin Res)

These genetic alterations were conspicuously absent in primary tumors, suggesting their potential role in metastatic progression. Our findings represent the first demonstration of CNV-driven oncogenic evolution in UTROSCTs, particularly implicating SWI/SNF complex dysregulation in metastatic competence.

2 months ago

Journal

ER (Estrogen receptor) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • ATRX (ATRX Chromatin Remodeler) • SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1) • SS18 (SS18 Subunit Of BAF Chromatin Remodeling Complex) • NCOA2 (Nuclear Receptor Coactivator 2) • NCOA3 (Nuclear Receptor Coactivator 3) • NCOA1 (Nuclear Receptor Coactivator 1)

3ms

ZFTA::NCOA1/2-rearranged Epithelioid Mesenchymal Tumor-A Phenotypically Distinct Myoepithelial-like Neoplasm Epigenetically Overlapping with Chondroid Lipoma. (PubMed, Mod Pathol)

In conclusion, ZFTA::NCOA1/2-rearranged epithelioid mesenchymal tumors represent a novel, morphologically distinct entity, genetically and epigenetically overlapping with chondroid lipoma. Expanded cohorts and long-term follow-up are necessary to clarify their precise classification and biologic behavior.

3 months ago

Journal

NCOA2 (Nuclear Receptor Coactivator 2) • RELA (RELA Proto-Oncogene) • ZFTA (Zinc Finger Translocation Associated) • NCOA1 (Nuclear Receptor Coactivator 1)

3ms

In Silico Characterization of Pathogenic ESR2 Coding and UTR Variants as Oncogenic Potential Biomarkers in Hormone-Dependent Cancers. (PubMed, Genes (Basel))

This integrative analysis prioritizes high-impact ESR2 variants that likely impair ERβ1 structure and shows context-dependent clinical effects. Despite their generally low frequency (except for rs4986938), prospective validation linking variant class to ERβ expression and survival outcomes is needed to support biomarker development and therapeutic applications.

3 months ago

Journal • BRCA Biomarker

ER (Estrogen receptor) • BRCA (Breast cancer early onset) • NCOA1 (Nuclear Receptor Coactivator 1)

4ms

Transcriptomic Profile of the Trastuzumab-Resistant Breast Cancer Cell Line BT-474 (PubMed, Mol Biol (Mosk))

The changes identified indicate a complex reprogramming of transcriptional activity affecting cell cycle processes, DNA repair, metabolism, and the epithelial-mesenchymal transition. The findings expand our understanding of the molecular mechanisms of trastuzumab resistance and open prospects for the development of novel therapeutic strategies to overcome drug resistance in HER2-positive breast cancer.

4 months ago

Preclinical • Journal

HER-2 (Human epidermal growth factor receptor 2) • POLD1 (DNA Polymerase Delta 1) • POLD2 (DNA Polymerase Delta 2) • YBX1 (Y-Box Binding Protein 1) • E2F1 (E2F transcription factor 1) • FSTL1 (Follistatin Like 1) • HEY1 (Hes Related Family BHLH Transcription Factor With YRPW Motif 1) • NFIC (Nuclear Factor I C) • TFAP2A (Transcription Factor AP-2 Alpha) • NCOA1 (Nuclear Receptor Coactivator 1)

HER-2 positive

Herceptin (trastuzumab)

4ms

Clinicopathologic and Molecular Genetic Features of Spindle Cell Rhabdomyosarcoma harboring ZFP64::NCOA2/3 fusions: A Series of 14 Cases. (PubMed, Mod Pathol)

We conclude that SCRMS with ZFP64::NCOA2/3 fusions represent a distinct, clinically aggressive sarcoma, characterized by fascicular and sometimes round cell morphology, occasional chondro-osseous differentiation and variable skeletal muscle marker expression. Recognition of this emerging subtype of SCRMS may have prognostic and therapeutic implications.

4 months ago

Journal

ALK (Anaplastic lymphoma kinase) • MEIS1 (Meis Homeobox 1) • TFCP2 (Transcription Factor CP2) • MYOD1 (Myogenic Differentiation 1) • NCOA2 (Nuclear Receptor Coactivator 2) • NCOA3 (Nuclear Receptor Coactivator 3) • VGLL3 (Vestigial Like Family Member 3) • NCOA1 (Nuclear Receptor Coactivator 1)

4ms

PRRX1-rearranged Fibroblastic Tumors: A Clinicopathologic and Molecular Study of 18 Cases Including a Novel PRRX1::EP300 Fusion. (PubMed, Am J Surg Pathol)

All but 1 tumor harbored a PRRX1::NCOA1 fusion, while 1 case harbored a novel PRRX1::EP300 fusion. We herein provide additional data on these exceptionally uncommon tumors, expand their molecular spectrum, and compare them to their close morphologic mimics to aid in accurate diagnosis and avoid confusion with potentially more aggressive neoplasms.

4 months ago

Journal

RB1 (RB Transcriptional Corepressor 1) • EP300 (E1A binding protein p300) • SOX10 (SRY-Box 10) • PRRX1 (Paired Related Homeobox 1) • NCOA1 (Nuclear Receptor Coactivator 1)

5ms

PRRX1-Rearranged Mesenchymal Tumor: A Case Report and Review of the Literature. (PubMed, Pediatr Dev Pathol)

However, we report the first pediatric case in an 11-year-old patient presenting with 5.5 cm mass in the head and neck region. Our case is also the second reported case of a PRRX1 (exon 1)::NCOA1 (exon 15) fusion transcript to date.

5 months ago

Journal

PRRX1 (Paired Related Homeobox 1) • NCOA1 (Nuclear Receptor Coactivator 1)

5ms

Interconnected study of molecular pathways: miR-137 as a central element at the intersection of lipid metabolism and prostate carcinogenesis. (PubMed, Einstein (Sao Paulo))

This study elucidates the possibility that miR-137 subtly modulates metabolic genes in prostate cancer, suggesting its latent therapeutic potential as a biomarker for disease progression.

5 months ago

Journal

MBD4 (Methyl-CpG Binding Domain 4, DNA Glycosylase) • ESRRA (Estrogen Related Receptor Alpha) • NCOA2 (Nuclear Receptor Coactivator 2) • NCOA3 (Nuclear Receptor Coactivator 3) • PPARA (Peroxisome Proliferator Activated Receptor Alpha) • PPARGC1A (PPARG Coactivator 1 Alpha) • PPARGC1B (PPARG Coactivator 1 Beta) • NCOA1 (Nuclear Receptor Coactivator 1)